TIDMIIG
RNS Number : 3779K
Intuitive Investments Group plc
21 December 2022
Intuitive Investments Group plc
Final Results
Notice of Annual General Meeting
Intuitive Investments Group plc (AIM: IIG) ("IIG" or the
"Company"), a closed-end investment company focussed on the life
sciences sector, announces its final results for the year to 30
September 2022. The full report and accounts (the "Report") can be
viewed by clicking on the following link:
https://iigplc.com/financial-reports/
Annual General Meeting
The Report also includes the notice of the Company's Annual
General Meeting, which will be held at the Parklands Hotel &
Country Club, Crookfur Park, Ayr Road, Newton Mearns, Glasgow G77
6DT on 17 January 2023 at 10.30 am.
Financial highlights
14 December
30 September 31 March 30 September 31 March 2020
2022 2022 2021 2021 Flotation
Net Assets
(GBP) 12.93 million 12.33 million 8.14 million 7.90 million 7.59 million
Investments
(GBP) 11.16 million 10.40 million 5.74 million 3.93 million NA
Cash (GBP) 1.55 million 1.91 million 2.57 million 3.90 million 7.59 million
NAV per share 18.00p 18.73p 20.14p 19.55p 18.78p
Increase/(decrease)
from previous
period end (3.90)% (6.96)% 2.99% 4.12% NA
Operational highlights
-- Acquisition of Touchless Innovation Ltd, including its wholly
owned subsidiary Touch-Less Hygiene UK Ltd and the business and
assets of Sanoserv International Franchising Ltd (trading as
Sanondaf).
-- Subscription to raise GBP607,000 by the issue of 2.76 million
new ordinary shares at a price of 22 pence per share, principally
subscribed for by directors of IIG.
-- Investment in Ocutec Ltd, a private company in the late-stage
portfolio, at a cost of GBP250,000.
-- The follow-on investment in Pneumowave Ltd resulting in an uplift in valuation of GBP454,000.
For further information, please contact:
Intuitive Investments Group plc www.iigplc.com
Julian Baines, Chairman Via Walbrook PR
Robert Naylor, CEO
SP Angel Corporate Finance LLP
- Nominated Adviser +44 (0) 20 3470 0470
Jeff Keating / David Hignell / Kasia
Brzozowska
Turner Pope Investments (TPI) Ltd
- Broker +44 (0) 20 3657 0050
Andrew Thacker / James Pope
Walbrook PR Limited - Media & Investor +44 (0)20 7933 8780 or intuitive@walbrookpr.com
Relations
+44 (0) 7980 541 893 / +44 (0)
Paul McManus / Sam Allen 7502 558 258
About Intuitive Investments Group plc
Intuitive Investments Group plc is an investment company seeking
to provide investors with exposure to a portfolio concentrating on
fast growing and/or high potential Life Sciences businesses
operating predominantly in the UK, continental Europe and the US,
utilising the Board's experience and in particular that of the
Chairman of the Investment Committee, David Evans, to seek to
generate capital growth over the long term for shareholders.
Regulatory Information
This Announcement contains inside information for the purposes
of the UK version of the market abuse regulation (EU No. 596/2014)
as it forms part of United Kingdom domestic law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR").
Intuitive Investments Group Plc
Chairman and Chief Executive's Report
Background
We are pleased to report the year end results to 30 September
2022. Julian Baines replaced David Evans as Chairman of the Company
in February 2022 with David becoming Chair of the Investment
Committee at that time.
Market commentary
The macro-environment continues to be challenging in the small
cap healthcare sector. During the year under review the AIM
All-Share (AXX) index fell by 35.0%. By comparison, the Company's
NAV fell 10.6%.
As we noted in our interim statement, a handful of small cap
healthcare companies were overvalued, often driven by anticipation
of COVID-related revenues, but we had not invested in these
companies. The subsequent mark down in small-cap healthcare has
been indiscriminate and not driven by fundamentals.
Another notable trend in the healthcare sector has been the
relative underperformance of the share prices of small cap
companies compared to large cap companies. This is partly a
function of generalist investors seeking defensive and liquid
characteristics of large cap healthcare companies. This
differential in performance is unsustainable, not least as we
believe the large cap companies will begin to exploit this relative
valuation gap by acquiring small and mid-sized companies. We have
begun to see some M&A activity in the sector.
Opportunity
Rather than viewing the small cap healthcare sector's
performance with dejection, we view this as an opportunity to
invest in companies, both private and publicly traded, which are
below their long-term value. Moreover, we perceive there is unmet
medical need and the need for innovation in hygiene, sanitisation
and healthcare-associated infection prevention sector. Therefore,
we will look to capitalise on this opportunity around infection
prevention, building on the foundation we have in our investment in
Sanondaf. We also recognise that overheads in many publicly traded
small cap companies is too high and not an efficient use of
capital, therefore we will look to acquire or merge if there is a
strategic logic.
Reliable statistics as to the cost of healthcare-associated
infections are difficult to source as the impacts are multifaceted,
for example, the additional length of stay in hospital, further
interventions needed as management of infection invariably involves
use of broad-spectrum antibiotics and attributing mortality.
However, there is reporting of certain infections. For example, The
UK Health Security Agency (UKHSA) reported that in the year to
March 2022 compared to year to March 2020, the year prior to the
COVID pandemic, E. coli and meticillin resistant Staphylococcus
aureus cases were lower, Klebsiella spp., Pseudomonas aeruginosa
and meticillin sensitive Staphylococcus aureus were similar and
Clostridioides difficile infection counts were at a nine-year
high.
The resulting recommendation of the UKHSA is that control
efforts in the hospital setting must be maintained or strengthened,
while increasing attention on healthcare interventions in the
community and the interface between hospital and community
infection control teams improved.
Sanondaf has a technology which provides excellent disinfection
capability with very quick turnaround times, particularly when
compared to competitor products. The company's service and machines
are cost effective and can be used in both community and hospital
settings - truly disinfection for all.
Corporate performance review
Sanondaf has a diverse customer base with over 60 customers,
including the NHS, serviced through its head office. It has an
extensive network of 25 franchisees in the UK and operates across
ten countries. Management accounts for Sanondaf, to 30 September
2022 show revenue of GBP1,893,000 and profit before tax of
GBP518,000.
There has been a reduction in revenues in a post-COVID
environment which was exacerbated by Sanondaf's major customer
going through a change of ownership with this followed by
industrial action, resulting in significantly reduced revenues. We
and the management team had anticipated an element of this
reduction in revenue due in a post-COVID environment, but
anticipated this would be more than matched by the opportunity in
international master franchise sales.
However, we have found these international sales lead times are
extending, again in part due to a post-COVID related malaise. We
remain confident about the growth prospectus for the international
business in the medium-term, but in the short-term these
opportunities are yet to be realised, we are therefore having
constructive discussions with the vendors regarding the deferred
consideration.
In addition, Sanondaf has evolved its business model to include
the sale of machines and consumable supply direct to customers,
including the NHS, allowing Sanondaf to capture sales at a higher
margin.
Unquoted investments
The unquoted portfolio continues, in the main, to be held either
at cost, plus accrued interest if applicable, or the valuation of
the most recent investment round. Both Axol Bioscience Ltd and
Momentum Ltd have raised additional capital. This is at the same
valuation as the round in which IIG participated and therefore
there is no change in valuation. Three investments were made during
the year, Sanondaf, Ocutec Ltd and a follow-on investment into
Pneumowave Ltd. The follow-on investment in Pneumowave Ltd has
resulted in an uplift in valuation of GBP454,124. Further details
of the companies in the unquoted portfolio are contained at the end
of this statement.
Listed portfolio at 30 September 2022
Valuation Valuation
as at as at
30 September 30 September Unrealised
2022 2021 loss
---------------------------- ------------- ------------- ------------
GBP GBP GBP
---------------------------- ------------- ------------- ------------
Evgen Pharma plc 65,625 126,955 (61,330)
Light Science Technologies
Holdings plc 863,200 1,328,000 (464,000)
Microsaic Systems plc 88,400 500,000 (411,600)
Midatech Pharma plc 26,250 91,000 (64,750)
Polarean Imaging plc 175,000 429,166 (254,166)
Shield Therapeutics plc 75,000 325,078 (250,078)
Trellus Health plc 29,750 375,000 (345,250)
Yourgene Health plc 71,321 221,888 (150,567)
Closing fair value 1,394,546 3,397,087 (2,002,541)
---------------------------- ------------- ------------- ------------
The publicly traded portfolio has not performed well. As noted
above we do not perceive that any of our investments achieved
excessive valuations, but have been marked down indiscriminately in
the post-COVID small cap healthcare sell off. We believe volatility
will be a feature in the small cap healthcare sector and as quickly
as companies de-rated there is the potential to appreciate,
particularly with good stock specific news such as FDA approvals
for Polarean Imaging plc, further licensing deals in other disease
states for Evgen plc, roll-out of innovative diagnostic tests in
Yourgene plc and customer wins with improved efficiency and cost
savings through telemedicine in Trellus Health plc. Light Science
Technologies plc has made progress, although there have been
significant headwinds, as seen by their latest trading update.
Financial performance
NAV per share has decreased by 10.6% from the previous year end.
Net Assets were GBP12,934,00, including investments of
GBP11,160,000 and cash of GBP1,553,000
There is net deficit income of GBP1,073,000, comprising
unrealised losses of GBP1,493,000, realisation of publicly traded
companies of GBP76,000, interest from the convertible loan notes in
aggregate of GBP148,000 and management fees received of GBP31,000.
The administrative costs of the business were GBP494,000 for the
year, which included one off costs of GBP 94,000 in relation to the
acquisition of Touchless Innovation . Overall retained loss was
GBP1,158,000.
Given the cash and liquid investments compared to the
administrative costs, the Company has adequate working capital for
a number of years. The Board does not propose to declare a
dividend.
Change to investment policy
We are proposing, as part of the Notice of Annual General
Meeting, at the end of the report and accounts, to remove the
investment restriction that no investment or group of investments
in the same company or group of companies will represent more than
45% of NAV. We believe this change will allow the Board more
flexibility in generating shareholder returns.
People
We have an excellent Board and Advisory Panel, which we believe
have the necessary skills to substantially grow the Company. We
wish to take this opportunity to thank the team for their
commitment and hard work during this initial period.
Outlook
Although COVID appears to be in the distant past, it highlights
the need for effective products and services in hygiene,
sanitisation and hospital acquired infection prevention sector. We
perceive we have an opportunity to exploit this need by building an
infection prevention business on the foundation we have in our
investment in Sanondaf. This presents a real opportunity of
providing shareholders excellent returns in the medium term.
Julian Baines Robert Naylor
Chairman Chief Executive Officer
21 December 2022
Later stage investments
BioQ Pharma Incorporated ("BioQ") ( www.bioqpharma.com )
Investment of US$1 million by way of unsecured convertible loan
notes and warrants, valued at cost plus accrued interest.
BioQ has raised more than $30 million in subscription for the
CLN and is looking to prepare for a fundraising in the Series E
ordinary shares. A further update is expected by the company before
the calendar year end.
BioQ is a commercial-stage, medical device and pharmaceutical
company, addressing the infusible drugs market. BioQ's proprietary
Invenious(TM) platform comprises a "connect-and-go" drug-device
system combination, which can be utilised to improve the delivery
of infusible medicines. BioQ's platform includes a bespoke
unit-dose delivery solution for infusible drugs, whereby a diluent
delivery system and administration line are combined in one
self-contained, ready-to-use presentation. The key benefits of the
platform include reduced cost and complexity compared to current
infusion techniques.
Touchless Innovations Ltd ("Sanondaf") ( www.sanondaf.co.uk
)
Investment of GBP6.36 million to acquire the entire issued share
capital, held at fair value, for which cost is deemed the most
appropriate basis of measurement.
Sanondaf is a market-leading provider of specialist disinfection
and decontamination services operating in 10 countries and has 25
regional sites in the UK. Treatments are non-corrosive, contain no
toxic ingredients and Sanondaf's application methods ensure they
are not harmful to people, animals or the environment. It is safe
for use in all settings, including operating theatres, critical
care units, and is CASA (Civil Aviation Safety Authority) approved.
Sanondaf's disinfection formula has proven efficacy against
pathogens, included, viruses, mould, bacteria and fungi.
Series A and B investments
Axol Bioscience Ltd ("Axol") ( www.axolbio.com )
Investment of GBP249,092 in A ordinary shares, held at fair
value, for which cost is deemed the most appropriate basis of
measurement. The company undertook a fundraising in April 2022 at
the same valuation as IIG's investment.
Axol produces high quality human cell products, particularly in
relation to pluripotent stem cell and critical reagents such as
media and growth supplements, which are sold to medical research
and drug discovery organisations. Axol also provides contract
research for example customising cell lines for customers, such as
reprogramming and differentiation. The Chairman of Axol is Jonathan
Milner, who was previously deputy chairman of Abcam plc.
CardiNor AS ("CardiNor") ( www.cardinor.com )
Investment of GBP122,260 in ordinary shares, held at fair value,
for which cost is deemed the most appropriate basis of
measurement.
CardiNor has made excellent progress particularly with the
amount of money raised, which includes:
-- Elisa test CE marked with clear route to market in the Europe
and next generation magnetic test being developed.
-- RuO in the US, but distribution deal done with IBL and
talking to Labcorp. Going for full FDA approval.
Valuation is 80 million NOK c.GBP7 million. CardiNor is a
Norwegian biotech company established in June 2015 to commercialise
the development of secretoneurin ("SN"), an important new biomarker
for cardiovascular disease ("CVD"). SN is the only biomarker shown
to be associated with biological processes linked to cardiomyocyte
handling. This unique biological function explains why SN presents
as an independent and strong predictor of mortality in all major
patient cohorts, including ventricular arrhythmia, acute heart
failure, acute respiratory failure patients with CVD and severe
sepsis. CardiNor has completed development of a research assay
based on immunoassay technology to measure SN in blood and the
assay is under further clinical development, allowing it to obtain
a CE mark.
The Electrospinning Company Ltd ("TECL") (
www.electrospinning.co.uk )
Investment of GBP500,000 in ordinary shares, held at fair value,
for which cost is deemed the most appropriate basis of
measurement.
Held at cost, TECL is trading in line with management
expectations. TECL has a technology platform built around the
process of electrospinning, a technique for production of micro and
nano-fibre biomaterials from a variety of natural and synthetic
polymers, and a suite of post-processing technologies to convert
the biomaterials into medical device components. The core business
is the sale of product development and manufacturing services to
medical device companies. TECL is also using its know-how to
develop proprietary materials for targeted out-licensing
opportunities, aiming to capture more of the end-market value
created by its innovations and expertise.
Micrima Ltd ("Micrima") ( www.micrima.com )
Investment of GBP200,000 by way of convertible loan note held at
fair value, for which cost is deemed the most appropriate basis of
measurement.
Micrima is a commercial stage company which has developed a new
imaging method, the MARIA(R) system, based on radiofrequency
technology to improve early diagnosis of breast cancer. Micrima
continues to make progress, but has suffered some delays in its
commercial launch due to not achieving the requisite
sensitivity.
Momentum Bioscience Ltd ("Momentum") ( www.momentumbio.co.uk
)
Investment of GBP125,000 in preferred A ordinary shares, held at
fair value, for which cost is deemed the most appropriate basis of
measurement. Momentum undertook an additional subscription in
September 2022 at the same valuation as IIG's investment.
Momentum is developing a revolutionary rapid diagnostic test for
patients suspected of sepsis, an infection of the blood stream
resulting in symptoms including a drop in a blood pressure,
increase in heart rate and fever. Momentum's SepsiSTAT(R) system
enables reporting of the presence or absence and 'pan gram
identification' of viable organisms in just two hours, helping
direct the right antimicrobials. The system also provides a pure
concentrate of growing organisms for further analysis. Faster
testing in suspected sepsis patients can reduce mortality,
accelerate hospital discharge, lower hospital costs, and reduce the
incidence of antimicrobial resistance. SepsiSTAT(R) is a diagnostic
test that runs from a sample of whole blood before any culturing
steps are taken and is currently being studied in clinical practice
with highly encouraging early results indicating competitive
sensitivity versus the current standard of care. Over 120 million
blood tests for sepsis are run annually representing a market
potential of over GBP1 billion.
Ocutec Ltd ("Ocutec") ( www.ocutec.com )
Investment of GBP250,000 in ordinary shares, held at fair value,
for which cost is deemed the most appropriate basis of
measurement.
Ocutec has patented technology covering the formulation of novel
contact lens products, contact lens comfort solutions and injection
moulding technology for rapid manufacturing. Ocutec is based in
Glasgow, and has been operating since 2006, having been spun out of
the University of Strathclyde.
PneumoWave Ltd ("PneumoWave") ( www.pneumowave.com )
Investment of GBP904,124 in new ordinary shares, held at fair
value, for which last investment round is deemed the most
appropriate basis of measurement.
IIG invested GBP100,000 by way of convertible loan notes which
converts at a 15% discount to the Series A and GBP350,000 in the
pre-series A funding round. The Series A round has completed
leading to an increase in valuation of GBP454,124.
PneumoWave, which was incorporated in February 2018, is
developing an innovative remote respiratory monitoring platform
comprising a small, chest-worn biosensor and AI-driven data
analysis/alerting software for the early detection, prediction, and
prevention of adverse events in respiratory patients, both in
hospitals and at home. In 2020, PneumoWave was awarded Breakthrough
Medical Device designation from the U.S. Food and Drug
Administration for the development of the device, which is designed
to monitor breathing in real-time to a clinical standard of
care.
The specially designed wireless biosensor is one of the smallest
available and transmits data to the cloud using a data hub or
smartphone, alerting the patient, their household members, doctor,
nurse, or emergency services where life-threatening changes occur.
PneumoWave's technology will be able to accurately monitor large
numbers of patients in any location at any time.
Intuitive Investments Group Plc
Statement of Comprehensive Income
For the year ended 30 September 2022
Year ended Period ended
30 September 30 September
2022 2021
GBP GBP
Investment income
Interest Income realised 55,181 -
Interest income unrealised 92,841 110,344
Unrealised gains/(losses) due -
to FX 165,831
Gains on realised investments 75,831 89,876
Gains/(losses) on Investments
at fair value (1,493,204) 821,214
Management Fees 30,642 34,084
-------------- --------------
(1,072,878) 1,055,518
Total administrative expenses (494,291) (324,153)
-------------- --------------
Profit/(Loss) before tax (1,567,169) 731,365
Corporation tax 408,686 (170,447)
-------------- --------------
Profit/(loss) for the year (1,158,483) 560,918
Other comprehensive income - -
-------------- --------------
Total comprehensive income for
the year attributable to owners
of the company (1,158,483) 560,918
Earnings per share from continued
operations
Basic profit/(loss) per share
- pence (2.01)p 2.22p
Diluted profit/(loss) per share
- pence (2.01)p 2.22p
Intuitive Investments Group Plc
Statement of Financial Position
As at 30 September 2022
As at As at
30 September 30 September
2022 2021
ASSETS GBP GBP
Non-current assets
Investments 11,159,530 5,737,353
Deferred tax asset 238,239 10,221
-------------- --------------
11,397,769 5,747,574
-------------- --------------
CURRENT ASSETS
Trade and other receivables 23,791 42,345
Cash and cash equivalents 1,553,100 2,566,793
-------------- --------------
1,576,891 2,609,138
-------------- --------------
TOTAL ASSETS 12,974,660 8,356,712
EQUITY
Shareholders' Equity
Called up share capital 720,646 404,418
Deferred shares 47,500 47,500
Share premium 12,619,428 6,985,736
Other reserves 144,399 144,399
Retained Earnings (597,565) 560,918
-------------- --------------
Total Equity 12,934,408 8,142,971
-------------- --------------
LIABILITIES
Current liabilities
Trade and other payables 40,252 33,073
Non current liabilities
Deferred tax liabilities - 180,668
-------------- --------------
40,252 213,741
-------------- --------------
-------------- --------------
TOTAL EQUITY AND LIABILITIES 12,974,660 8,356,712
Net asset value per share 0.1800 0.2014
Intuitive Investments Group Plc
Statement of Changes in Equity
As at 30 September 2022
Called Deferred
up Shares Share Other Retained Total
Share Premium reserves Earnings equity
capital
GBP GBP GBP GBP GBP GBP
Balance at 11 June 2020 - - - - - -
Profit for the period - - - - 560,918 560,918
Issue of shares during
the period 451,918 - 7,130,135 - - 7,582,053
Subdivision of share
capital (47,500) 47,500 - - - -
Warrants issued on
admission - - (144,399) 144,399 - -
------------ ------------ ------------ ------------ -------------- --------------
Balance at 30 September
2021 404,418 47,500 6,985,736 144,399 560,918 8,142,971
Loss for the year - - - - (1,158,483) (1,158,483)
Issue of shares during
the year 316,228 - 5,633,692 - - 5,949,920
------------ ------------ ------------ ------------ -------------- --------------
Balance at 30 September
2022 720,646 47,500 12,619,428 144,399 (597,565) 12,934,408
Intuitive Investments Group Plc
Statement of Cash Flows
For the year ended 30 September 2022
Year ended Period ended
30 September 30 September
2022 2021
GBP GBP
(Loss)/Profit before tax from continuing
operations (1,567,169) 731,365
Adjusted by:
Interest income (92,841) (110,344)
Gain on disposal (73,831) (89,876)
Fair value movement 1,325,371 (821,214)
------------ ------------
(408,470) (290,069)
Changes in working capital
(lncrease)/decrease in trade and
other receivables 18,554 (42,345)
lncrease/(decrease) in trade and
other payables 7,180 33,073
------------ ------------
Cash generated from continuing
operations (382,736) (299,341)
------------ ------------
Net cashflow from operating activities (382,736) (299,341)
Cash flows from investing activities
Purchase of investments (1,449,805) (5,055,770)
Proceeds from sale of investments 211,847 339,851
------------ ------------
Net cash flows from investing activities (1,237,958) (4,715,919)
Cash flows from financing activities
Net proceeds from share issues 607,001 7,582,053
------------ ------------
Net cash inflow from financing
activities 607,001 7,582,053
------------ ------------
Net increase/(decrease) in cash
and equivalents (1,013,693) 2,566,793
Cash and cash equivalents at beginning -
of period 2,566,793
------------ ------------
Cash and cash equivalents at end
of period 1,553,100 2,566,793
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FR FLFVRFALIFIF
(END) Dow Jones Newswires
December 21, 2022 02:00 ET (07:00 GMT)
Intuitive Investments (LSE:IIG)
Historical Stock Chart
From Apr 2024 to May 2024
Intuitive Investments (LSE:IIG)
Historical Stock Chart
From May 2023 to May 2024